Rosetta CEO Says Accelerated IPO Report Inaccurate, Declines to Reaffirm 07 Float | GenomeWeb

Rosetta Genomics Chairman and CEO Isaac Bentwich this week described as "misleading and inaccurate" an article in an Israeli newspaper reporting that his company was planning a June 2006 initial public offering on the Nasdaq, but fell short of denying the story outright.

He also declined to reaffirm statements he made to RNAi News late last year about a potential IPO planned for 2007, raising questions as to whether the company has altered its plans or prerequisites to float its shares in the US.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.